 NPS is committed to developing new treatment options for patients with rare gastrointestinal and endocrine disorders who have few, if any, therapeutic options. We have received approval for Gattex®(U.S.)/Revestive®(EU) (teduglutide [rDNA origin]) for injection for the treatment short bowel syndrome patients who are dependent on parenteral support. We are also developing Natpara® (recombinant human parathyroid hormone (rhPTH (1-84)) for hypoparathyroidism and plan to submit our Biologic License Application to the FDA in 2013. We have provided information within this section to further educate you about SBS and hypoparathyroidism. |
“At NPS Pharmaceuticals, addressing patients' unmet needs is central to everything we do. NPS is deeply committed to ensuring patients with rare diseases have burden-free access to our FDA-approved treatments. NPS Advantage is a support program helping each patient and their healthcare professionals get the answers they need about NPS therapies.”
Eric Pauwels
Sr. Vice President & Chief Commercial Officer
